CareDx Advances Global Transplant Patient Care at ESOT Congress 2023
14.9.2023 09:00:00 EEST | Business Wire | Press release
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.
The latest scientific advances in global transplantation using CareDx’s AlloSeq cfDNA testing solutions are being showcased across eleven abstracts, including four posters, two moderated e-posters, one focus group, and five oral presentations. CareDx is hosting an educational symposium for medical professionals demonstrating the clinical utility of AlloSeq cfDNA. AlloSeq cfDNA is offered to European and other customers outside of the United States, to detect donor-derived cell-free DNA (dd-cfDNA) for the surveillance of allograft rejection risk in solid organ transplant patients.
“We are proud to attend ESOT Congress 2023, a preeminent European transplant conference, and share the latest data demonstrating the use of AlloSeq cfDNA,” said Reg Seeto, CEO and President of CareDx. “Through our partners and work with transplant centers internationally, we have made excellent progress in improving access to AlloSeq cfDNA for the benefit of organ transplant patients globally.”
AlloSeq cfDNA data being presented at ESOT Congress 2023
|
Abstract Title |
|
KIDNEY |
|
|
|
|
|
|
|
|
HEART |
|
|
|
LUNG |
|
|
MULTI-ORGAN |
|
“It is gratifying seeing the impact of dd-cfDNA on clinical practice and patient care. We’ve seen how the information from AlloSeq cfDNA testing not only helps clinicians in their decision-making, but also empowers transplant recipients, providing them control, understanding, and greater peace of mind on the status of their transplanted organ,” Dr. Thomas Schachtner, Transplant Specialist, University Hospital Zurich, Switzerland.
CareDx will review the latest data on AlloSeq cfDNA during an ESOT Congress 2023 Industry Satellite Symposium titled, “Adopting dd-cfDNA for Solid Organ Surveillance: Raising the Standards of Transplant Care.” The symposium will be held live and streamed virtually on ESOT’s Congress platform on Sunday, September 17, 2023. Dr. Titte Srinivas, Chief Medical Officer at CareDx and Dr. Georg Böhmig, Associate Professor at the Medical University Vienna, Austria, will moderate the session. Speakers include:
- Maarten Naesens, MD, PhD, Clinical Director, Professor of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium
- Alexandre Loupy, MD, PhD, Professor of Nephrology and Epidemiology, Necker Hospital, PITOR (Paris Institute for Transplantation & Organ Regeneration), France
- David Cucchiari, MD, PhD, Associate Professor of Nephrology, Hospital Clínic Barcelona, Catalonia, Spain
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, and with a European headquarter office in Stockholm, Sweden, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with the Company’s AlloSeq cfDNA solutions and its participation at the 2023 ESOT Congress. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its AlloSeq cfDNA solutions, or its participation at the 2023 ESOT Congress; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed by CareDx with the SEC on August 8, 2023, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913528887/en/
Contact information
CareDx, Inc.
Media Relations
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Greg Chodaczek
investor@caredx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 17:03:00 EET | Press release
BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inventor Dr. Farid Bennis, the technology uses a dissolvable effervescent tablet to create a buffered solution that helps protect peptides during gastrointe
Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 17:00:00 EET | Press release
Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftBank’s strategy for a Ubiquitous Network. The majority of Sceye’s initial fleet will provide mobile broadband throughout Japan, while a subset will also establish a Free Space Optical (FSO) network in the stratosphere. These deploym
SharkNinja Brings Its All-Star Neighbors and Fans Home for the Holidays3.11.2026 17:00:00 EET | Press release
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today unveiled the final spot in its first-ever SharkNinja holiday campaign, starring global brand ambassadors David Beckham, Tom Brady, Kevin Hart, and Aryna Sabalenka. The campaign, “There’s No Home Like a SharkNinja Home,” puts the ambassadors’ own fandom and love of Shark and Ninja products at the center of a holiday house-sitting assignment that gets a little out of hand and invites fans along for the fun. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103325477/en/ David Beckham, Tom Brady, Kevin Hart, and Aryna Sabalenka celebrate a shared love and fandom of Shark and Ninja products in SharkNinja’s first-ever holiday campaign, “There’s No Home Like a SharkNinja Home” Created by SharkNinja’s in-house Creative Labs team and produced by Studio 99, the holiday campaign builds on SharkNinja’s Neighbors series, which debuted in 2025 with Beckham
Andersen Consulting Enhances Transformation Capabilities with Bakia Consulting3.11.2026 16:30:00 EET | Press release
Andersen Consulting advances its business transformation capabilities through a Collaboration Agreement with Bakia Consulting, a firm specializing in finance function transformation. Headquartered in Paris with capabilities in Singapore and Hong Kong, Bakia Consulting has helped large corporations and financial institutions redesign their finance functions, addressing operating models, organizational structures, processes, and digital systems. The firm combines project management and change management, working alongside clients to develop solutions and sustain change. Bakia Consulting also advises on financial and non-financial management models, process optimization, and digital tools. “Finance functions are being asked to deliver better insight, operate more efficiently, and adapt to changing business needs, often at the same time,” said Romain Dubuisson, partner at Bakia Consulting. “We work closely with clients to develop solutions that reflect their operational realities, combinin
Organigram to Acquire Aurora and Establish a Global Cannabis Leader3.11.2026 16:16:00 EET | Press release
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”). The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings, Inc. (“Curaleaf”) of its intention to launch a hostile takeover bid for Aurora (the “Unaffected Price”), and a 21% premium relative to the current bid value of the Curaleaf hostile offer3 (the “Hostile Bid”) as most recently amended on October 6, 2026, which was unanimousl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom